• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Cybin Inc.

    8/27/24 5:22:14 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYBN alert in real time by email
    SC 13G 1 cybn13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)

    Cybin Inc.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    23256X100

    (CUSIP Number)

    March 14, 2024

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 23256X100

     

     

    1.Names of Reporting Persons.

    Logos Global Management LP

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 40,000,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 40,000,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 40,000,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) IA, PN

     2 
    CUSIP No. 23256X100

     

     

    1.Names of Reporting Persons.

    Logos Global Management GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 40,000,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 40,000,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 40,000,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) HC, OO

     

     3 
    CUSIP No. 23256X100

     

     

    1.Names of Reporting Persons.

    Arsani William

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 40,000,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 40,000,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 40,000,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 23256X100

     

     

    1.Names of Reporting Persons.

    Logos Global Master Fund LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ___X__

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 40,000,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 40,000,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 40,000,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     5 
    CUSIP No. 23256X100

     

     

    1.Names of Reporting Persons.

    Logos GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 40,000,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 40,000,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 40,000,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) OO

     

     6 
    CUSIP No. 23256X100

     

     

    Item1.
    (a)Name of Issuer

    Cybin Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    Logos Global Master Fund LP (“Global Fund”), Logos Global Management LP (“Logos Global”), Logos GP LLC (“Logos GP”), Logos Global Management GP LLC (“Logos Global GP”), and Arsani William (collectively, the “Filers”).

     

    Logos Global is the investment adviser to investment funds, including Global Fund. Logos Global GP is the general partner of Logos Global. Dr. William is a control person of Logos Global and Logos Global GP.

     

    The Filers are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. In addition, filing this Schedule 13G on behalf of Global Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    One Letterman Drive, Building C, Suite C3-350, San Francisco, California 94129

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Shares.

     

    (e)The CUSIP number of the Issuer is: 23256X100.
     7 
    CUSIP No. 23256X100

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to Logos Global.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G) as to Logos Global GP and Dr. William.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The percentages reported in this Schedule 13G are based on 759,692,495 Common Shares outstanding as of July 15, 2024, as reported in the Management Information Circular filed by the Issuer as an Exhibit to Form 6-K on August 15, 2024.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Global Fund holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of Logos Global, Logos Global GP and Dr. William:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Global Fund and Logos GP:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     8 
    CUSIP No. 23256X100

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 27, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     
    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arasani William
    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

     9 
    CUSIP No. 23256X100

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Logos Global Management LP, a Delaware limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Act, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: August 27, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     
    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

     

    Get the next $CYBN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYBN

    DatePrice TargetRatingAnalyst
    3/13/2025$35.00Buy
    Guggenheim
    11/22/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    11/19/2021Buy → Hold
    Maxim Group
    10/5/2021$7.00Outperform
    Oppenheimer
    8/26/2021$9.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYBN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

      - Thermo Fisher Scientific, the world leader in serving science, is providing Phase 3 capsule clinical supply and will support future commercial manufacturing efforts for CYB003 - - Production of both drug substance and drug product will be performed at Thermo Fisher's U.S. pharma services manufacturing sites - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has engaged Thermo Fisher Scientific ("Thermo Fisher"), the world leader in serving science, to support the Phase 3 clinical

      5/15/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

      Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2025. Mr. Drysdale's fireside chat will be webcast live on Wednesday, May 21, 2025, at 1:40 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the

      5/14/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

      - Newly issued patent includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041 - - Cybin's growing intellectual property portfolio comprises more than 80 granted patents and over 230 pending applications - - Patient dosing continues in APPROACH, Cybin's first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder ("MDD") - - Second Phase 3 study, EMBRACE, is expected to begin mid-2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innova

      5/8/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Financials

    Live finance-specific insights

    See more
    • Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

      - 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of CYB003 - - Findings validate dosing regimen and confirm that CYB003's effects are highly durable and offer sustained relief for MDD patients - - CYB003 continues to be well-tolerated and demonstrates an excellent safety profile - - Cybin's Phase 3 PARADIGM TM multinational pivotal program evaluating the efficacy and safety of CYB003 has been initiated - - Company to

      11/18/24 7:00:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

      - Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET. The event will be hosted by Cybin's Chief Executive Officer, Doug Drysdale, and Cybin's Chief Medical Officer, Amir Inamdar, and will incl

      11/14/24 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

      - Breakthrough Therapy Designation ("BTD") provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration ("FDA") guidance on trial design, with the potential to significantly reduce drug development timelines - - First known BTD granted by the FDA for an adjunctive psychedelic based therapy for the treatment of Major Depressive Disorder ("MDD") - - Robust, sustained and statistically significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses (16mg) - - Impressive mean 22-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score from baseline at four months -

      3/13/24 6:00:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Cybin with a new price target

      Guggenheim initiated coverage of Cybin with a rating of Buy and set a new price target of $35.00

      3/13/25 7:34:44 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Cybin with a new price target

      HC Wainwright & Co. reiterated coverage of Cybin with a rating of Buy and set a new price target of $10.00 from $8.00 previously

      11/22/21 6:24:49 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin downgraded by Maxim Group

      Maxim Group downgraded Cybin from Buy to Hold

      11/19/21 8:09:52 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cybin Inc.

      SC 13G - CYBIN INC. (0001833141) (Subject)

      12/3/24 5:23:26 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cybin Inc.

      SC 13G/A - CYBIN INC. (0001833141) (Subject)

      11/14/24 7:51:22 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cybin Inc.

      SC 13G/A - CYBIN INC. (0001833141) (Subject)

      11/14/24 6:55:13 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

      - Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of MDD patients - - Patient dosing continues in APPROACH, Cybin's first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder ("MDD") - - Second Phase 3 study, EMBRACE, is expected to begin mid-2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform

      4/23/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

      - Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder ("MDD") imminently - - Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez as Vice President, Clinical Pharmacology - - Other recent additions to the team include project directors. project managers, and clinical monitoring managers, as well as previously announced senior leadership team hires, and program lead for CYB003 - - Strengthened team in place to support CYB003 pivotal trials, which will consist of three studies spanning up to 12 countries - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company")

      10/1/24 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

      Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) (Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on August 27, 2024 (the "Meeting"). There were 87 shareholders represented in person or by proxy at the Meeting holding 453,195,063 common shares, representing 59.66% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are

      8/27/24 7:01:00 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    SEC Filings

    See more
    • SEC Form 6-K filed by Cybin Inc.

      6-K - CYBIN INC. (0001833141) (Filer)

      5/15/25 5:23:23 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cybin Inc.

      SCHEDULE 13G/A - CYBIN INC. (0001833141) (Subject)

      5/15/25 4:15:24 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Cybin Inc.

      6-K - CYBIN INC. (0001833141) (Filer)

      5/14/25 5:22:40 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care